Shares of Verve Therapeutics (VERV 76.24%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly (LLY -1.40%) and Verve Therapeutics announced a "definitive agreement for Lilly to acquire Verve."Lilly offered $10.50 per share in cash, payable at the closing of the transaction. This represents a premium of around 113% to the 30-day volume-weighted average trading price of Verve stock for the period ending June 16, 2025.In addition, Verve shareholders will receive one n ...

Biotech stock Verve Therapeutics Inc (NASDAQ:VERV) is up 75.3% to trade at $10.99 at last check amid news that peer Eli Lilly (LLY) will buy the company for $10.50 per share, or roughly $1.3 billion. The pair have already been partnering on several drugs, with the move allowing Eli Lilly to push further into gene editing. VERV is now trading at its highest level since April 2024, and sports an 11.2% year-to-date lead. The shares have been using the $6 region and 100-day moving average as support in recent w ...

Core Viewpoint - Eli Lilly and Company has announced a definitive agreement to acquire Verve Therapeutics, a clinical-stage company focused on genetic medicines for cardiovascular disease, with the aim of transforming treatment from chronic care to a single-dose solution [1][2][3] Company Overview - Verve Therapeutics is developing gene editing medicines targeting atherosclerotic cardiovascular disease (ASCVD), with its lead program VERVE-102 focusing on the PCSK9 gene, which is linked to cholesterol levels [2][7] - VERVE-102 is currently in a Phase 1b clinical trial and has received Fast Track designation from the U.S. FDA, indicating its potential significance in treating conditions like heterozygous familial hypercholesterolemia [2][3] Acquisition Details - Under the acquisition agreement, Lilly will offer $10.50 per share in cash for Verve's outstanding shares, totaling approximately $1.0 billion, with potential additional contingent value rights (CVR) bringing the total to up to $13.50 per share, or approximately $1.3 billion [3][4] - The purchase price represents a premium of about 113% over Verve's 30-day volume-weighted average trading price as of June 16, 2025 [4] - The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions [3][4] Strategic Rationale - Lilly's acquisition of Verve is seen as a strategic move to enhance its capabilities in cardiometabolic disease and genetic medicines, aligning with Verve's vision to provide lifelong cardiovascular risk reduction through innovative treatments [1][3] - The collaboration is anticipated to accelerate the development of Verve's gene editing programs, addressing significant unmet medical needs in cardiovascular care [3][7] Shareholder Support - Verve's board of directors unanimously recommends that shareholders tender their shares in the tender offer, and key stakeholders representing approximately 17.8% of Verve's outstanding common stock have signed support agreements [5][4]

Investors might want to bet on Verve Therapeutics (VERV) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changi ...

Summary of Verve Therapeutics (VERV) FY Conference Call - June 09, 2025 Company Overview - **Company**: Verve Therapeutics - **Focus**: Gene editing for cardiovascular disease, specifically targeting lifelong cholesterol lowering to treat coronary heart disease Key Points and Arguments 1. **HEART-two Data Announcement**: The company recently disclosed data from the HEART-two trial, which showed promising results for their gene editing therapy aimed at lowering LDL cholesterol levels [3][4] 2. **Unmet Need**: Current cholesterol-lowering therapies have a high dropout rate, with up to 50% of patients discontinuing treatment within a year. Verve aims to provide a one-time therapy that offers lifelong efficacy [5] 3. **Efficacy Results**: In the HEART-two trial, the therapy demonstrated an LDL reduction of up to 60%, with a mean reduction of 59% in the highest dose group. All patients in this group experienced over 50% lowering [8][21] 4. **Safety Profile**: The therapy was well tolerated, with only one infusion-related reaction reported among 14 patients. No significant laboratory abnormalities were observed [8][9] 5. **Durability of Effect**: The company reported that the LDL reduction was sustained at 60% two years post-infusion, supporting the vision of a one-time therapy for atherosclerotic cardiovascular disease [10][11] 6. **Comparison of Products**: The difference between the first-generation product (VRRB101) and the second-generation product (VRRB102) lies in the delivery system, which has been improved to enhance safety and efficacy [12][14] 7. **Regulatory Environment**: Recent discussions with the FDA indicate a supportive stance towards gene editing technologies, particularly those addressing chronic diseases like atherosclerosis [45][48] 8. **Market Research Findings**: Surveys indicate a significant openness among patients and physicians towards a one-time gene editing therapy, with about one-third of patients preferring this option over traditional therapies [50][53] 9. **Cost of Manufacturing**: The estimated cost to manufacture the therapy is around $3 per dose, suggesting potential for flexible pricing strategies compared to traditional gene therapies [55][56] 10. **Partnership with Eli Lilly**: The company is preparing to present data to Eli Lilly for potential opt-in for further development, which could extend Verve's cash runway [62][69] Additional Important Insights - **Dosing Strategy**: The company is shifting towards fixed dosing rather than weight-based dosing, as the therapy primarily targets the liver [24][26] - **Long-term Safety Considerations**: The company believes that the low risk of off-target effects, combined with the significant risk of untreated cardiovascular disease, will favor the adoption of their therapy [40][41] - **Future Developments**: Verve is also working on additional products targeting ANGPTL3 and Lp(a), leveraging the same delivery system as VRRB102 [64][66] This summary encapsulates the critical insights from the conference call, highlighting the company's innovative approach to gene editing in cardiovascular disease and its potential impact on patient care and market dynamics.

From a technical perspective, Verve Therapeutics (VERV) is looking like an interesting pick, as it just reached a key level of support. VERV recently overtook the 200-day moving average, and this suggests a long-term bullish trend.The 200-day simple moving average is widely-used by traders and analysts, and helps establish market trends for stocks, commodities, indexes, and other financial instruments over the long term. The indicator moves higher or lower together with longer-term price moves, serving as a ...

Verve Therapeutics (VERV) closed the last trading session at $5.29, gaining 25.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24.75 indicates a 367.9% upside potential.The average comprises eight short-term price targets ranging from a low of $15 to a high of $39, with a standard deviation of $7.81. While the lowest estimate indicates an increase of 183.6% from the current pri ...

Verve Therapeutics (VERV) 2025 Conference June 04, 2025 09:20 AM ET Speaker0 Okay. Welcome everyone to twenty twenty five Jefferies Global Healthcare Conference. It it is my my name is Roger Song, one of the senior analysts covers MidCap biotech in US. And then it's my pleasure to have the next five star chat with our company, Zach, from the so excuse me. So from the Verve Therapeutics. So it it is a it is it is a very exciting timing for Verve because they just reported a very exciting data from the one tw ...

Investor Contact Jen Robinson Verve Therapeutics, Inc. jrobinson@vervetx.com Media Contact Ashlea Kosikowski 1AB ashlea@1abmedia.com Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. ET in New York, NY Goldman Sachs 46 Annual Global Healthcare Conference on Monday, June 9, 2025, at 11:20 a.m. ET in Miami, FL Live webcasts will be available in the investor section of the company's website at www.vervetx.com. The webcasts will be archived for 30 days following the fireside chats. ...

Summary of Verve Therapeutics (VERV) 2025 Conference Call Company Overview - **Company**: Verve Therapeutics - **Industry**: Biotechnology, specifically focusing on gene editing therapies for cholesterol reduction Key Points and Arguments Progress and Pipeline - Verve is developing one-time therapies aimed at lifelong cholesterol reduction through IV infusion targeting the PCSK9 gene [3][4] - Initial Phase 1 data shows well-tolerated safety and significant efficacy with LDL reductions of 50-60%, with one patient achieving a 69% reduction [4] - The company is also working on additional programs targeting ANGPTL3 and LPA, with updates expected in the second half of the year [5][6] Regulatory Environment - The new leadership at the FDA, particularly Dr. Prasad, is seen as an opportunity for Verve, aligning with their focus on meaningful clinical endpoints like LDL levels [10][11] - Verve's PCSK9 therapy is positioned to provide substantial value, potentially reducing coronary disease risk by 80-90% [12] Clinical Development - Transition from first-generation (Vrb 101) to second-generation (Vrb 102) therapies has improved safety profiles due to advancements in lipid nanoparticle delivery systems [15][16] - Ongoing dose escalation studies are expected to yield further efficacy data, with hopes of achieving higher LDL reduction percentages [19] Partnership with Eli Lilly - Verve has a partnership with Eli Lilly, which includes an opt-in decision expected in the second half of the year, where Lilly would cover a third of worldwide development costs and 50% of US commercialization expenses [21][22] - The partnership is focused on a multimodal pipeline for cardiovascular disease targets, including LPA and ANGPTL3 [23] Market Landscape and Competition - Despite the presence of oral medications for cholesterol reduction, Verve's one-time therapy addresses a significant unmet need, as many patients do not achieve treatment goals with existing options [29][30] - Patient and physician preferences indicate a strong demand for one-time therapies over daily pills [30][31] ANGPTL3 Target - The ANGPTL3 target is supported by strong genetic evidence and pharmacologic validation, with the potential to lower both LDL cholesterol and triglycerides [34] - Previous safety concerns with other ANGPTL3 therapies are attributed to specific drug-related issues rather than the target itself [36] Future Directions - Verve is optimistic about the upcoming data updates for both PCSK9 and ANGPTL3 programs, with plans to leverage learnings from previous studies to enhance study designs [40] - The company is also exploring monetization opportunities for its proprietary GalNAc LNP delivery technology, which has shown promising safety profiles [49][51] Competitive Landscape - The emergence of competitors like CRISPR in the gene editing space is acknowledged, with Verve focusing on differentiating its approach through established safety and efficacy data [38][53] Additional Important Insights - The ongoing trials and partnerships are critical for Verve's strategy to establish itself in the competitive landscape of cholesterol-lowering therapies [47][48] - The company remains confident in the potential of its therapies to address significant cardiovascular health challenges, particularly in light of the limitations of current treatment options [45][46]